Concentra Group Holdings Parent, Inc. (CON) company profile
Close on Nov 12, 2026Market cap $5.48BP/E 25.6Yield 0.58%
About Concentra Group Holdings Parent
Services-Specialty Outpatient Facilities, NEC, SIC 8093
Concentra provides occupational health services, employer health services, and direct-to-employer healthcare across the United States. Its core operations encompass three segments: occupational health centers, onsite health clinics, and other complementary businesses. The company delivers injury care and treatment for workers' compensation, physical therapy, and consumer health services. Its employer-focused solutions include pre-placement physical examinations, Department of Transportation certifications, substance abuse screenings, vaccinations, and workplace safety consultative services. The company also operates telemedicine platforms, affiliated pharmacy dispensing, and medical compliance programs. Concentra primarily serves employers across diverse industries, ranging from small businesses to Fortune 100 enterprises.
As of December 31, 2025, the company operated 628 stand-alone occupational health centers across 41 states and 411 onsite health clinics at employer worksites in 44 states. Overall, its healthcare delivery network extends across 47 states and the District of Columbia, supported by roughly 13,000 colleagues and affiliated clinicians who treat an average of 53,000 patients each business day. The provided text does not state the company's headquarters location.
Summary of the business section of Concentra Group Holdings Parent's latest annual report, written by StockData.
Company profile
Company
- Legal name
- Concentra Group Holdings Parent, Inc.
- Founded
- 1979
- Headquarters
- Addison, TX
- Address
- 5080 Spectrum Drive, Suite 1200w 75001
- Phone
- (972) 364-8000
- Website
- concentra.com
- Employees
- 13,133, Dec 31, 2025
- Industry
- Services-Specialty Outpatient Facilities, NEC
- Incorporated in
- Delaware
- Fiscal year ends
- December 31
- Auditor
- PricewaterhouseCoopers LLP, Dallas, Texas
Stock & identifiers
- Ticker
- CON
- Exchange
- NYSE
- IPO date
- Jul 26, 2024
- Shares outstanding
- 128M, Jul 31, 2026
- Public float
- $2.37B, Jun 30, 2025
- Filer category
- Large accelerated filer
- SEC CIK
- 2014596
- CUSIP
- 20603L102
- ISIN
- US20603L1026
- FIGI
- BBG01NBZ7QD9
- Share class FIGI
- BBG01NBZ7R83
- EIN
- 30-1006613
Executives and directors
Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years
| Name | Position | Shares owned |
|---|---|---|
| Matthew T. DiCanio | See Remarks, Director | 471,770 |
| Raymond Tanner Newton | EVP & Chief Financial Officer | 114,098 |
| Timothy F. Ryan | See Remarks | 148,834 |
| Jonathan P. Conser | See Remarks | 155,482 |
| Michael D. Rhine | See Remarks | 112,176 |
| Danielle Kendall | See Remarks | 101,440 |
| Giovanni Gallara | See Remarks | 153,502 |
| John Robert Anderson Jr. | See Remarks | 100,380 |
| John A. deLorimier | See Remarks | 147,559 |
| Michael A. Kosuth | See Remarks | 153,656 |
| Greg M. Gilbert | See Remarks | 148,834 |
| Thomas A. Devasia | See Remarks | 143,514 |
| Douglas R. McAndrew | See Remarks | 155,482 |
| Su Zan Nelson | See Remarks | 102,291 |
| Robert A. Ortenzio | Director | 5,852,211 |
| William Keith Newton | Director | 577,375 |
| Daniel Thomas | Director | 77,989 |
| Marc R. Watkins | Director | 24,729 |
| Cheryl Pegus | Director | 24,729 |
| Brigid A. Bonner | Director | 19,485 |
| Vipin Gopal | Director | 19,485 |
CEO pay and shareholder return
Pay versus performance table from the proxy statement
| Fiscal year | CEO total pay | CEO pay actually paid | Other executives (avg) | Value of $100 invested | Peer group |
|---|---|---|---|---|---|
| FY2025 | $7.40M | $7.39M | $3.05M | $89 | $110 |
| FY2024 | $7.08M | $6.33M | $3.53M | $88 | $93 |
“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.
Executive compensation, fiscal 2025
Summary compensation table from the latest proxy statement
| Executive | Salary | Stock awards | Incentive pay | Other | Total | vs. prior year |
|---|---|---|---|---|---|---|
| William K. Newton Chief Executive Officer (Principal Executive Officer) | $843.08K | $4.36M | $2.13M | $75.44K | $7.40M | +5% |
| Matthew T. DiCanio President and Chief Financial Officer (Principal Financial Officer) | $573.85K | $3.48M | $1.15M | $59.23K | $5.27M | -20% |
| John A. deLorimier Executive Vice President, Chief Information and Technology Officer | $450.00K | $1.16M | $675.00K | $28.28K | $2.31M | -18% |
| Timothy Ryan Executive Vice President and Chief Legal Counsel | $450.00K | $1.16M | $675.00K | $25.99K | $2.31M | – |
| John Anderson Executive Vice President, Chief Medical Officer | $450.00K | $1.16M | $675.00K | $25.76K | $2.31M | -18% |
Stock and option awards are grant-date fair values, not realized pay. “Other” includes pension value changes and all other compensation. Source proxy statement.
IPO
From the final prospectus (Form 424B4) and the first day of trading
Offering
- Type
- Initial public offering
- Final prospectus filed
- Jul 26, 2024
- Offer price
- $23.50
- Securities offered
- 22,500,000
- Gross proceeds
- $528.75M
- Exchange
- NYSE
- First trading day
- Jul 25, 2024
- First-day close
- $22.48-4.3%
- Lock-up ends (est.)
- Jan 21, 2025
“The initial public offering price is $23.50 per share of our common stock.”
Lock-up end is estimated as 180 days after the first trading day; the prospectus sets the actual terms.
Employees
Headcount reported in annual reports
“As of December 31, 2025, we had 13,133 colleagues and affiliated physicians and clinicians who support the delivery of an extensive suite of services, including 9,967 full-time and 32 part-time, and 3,134 per-diem employees.”
Corporate history
Events identified from SEC filings
| Date | Event | Details |
|---|---|---|
| Jun 2, 2025 | Acquisition / sale | Completion of acquisition or disposition of assets (8-K Item 2.01) |
| Mar 3, 2025 | Acquisition / sale | Completion of acquisition or disposition of assets (8-K Item 2.01) |
| Jul 26, 2024 | IPO | Initial public offering priced (424B4 prospectus) |
| Jul 24, 2024 | Listing | Registration of securities on an exchange (Form 8-A) |
See a number that looks wrong?